Elisabeth Bergen1, Anna S Berghoff1, Margaretha Rudas2, Peter Dubsky3, Catharina De Vries4, Claudia Sattlberger4, Robert M Mader1, Flora Zagouri5, Cornelia Sparber6, Florian Fitzal7, Michael Gnant3, Andrea Rottenfusser8, Christoph C Zielinski1, Matthias Preusser1, Guenther G Steger1, Rupert Bartsch1. 1. Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria. 2. Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Pathology, Medical University of Vienna, Austria. 3. Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Surgery, Medical University of Vienna, Austria. 4. Department of Radiotherapy, LKH Feldkirch, Austria. 5. Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, University of Athens, Greece. 6. Department of Medicine, LKH Kirchdorf, Austria. 7. Department of Surgery, KH Barmherzigen Schwestern Linz, Austria. 8. Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Radiotherapy, Medical University of Vienna, Austria.
Abstract
BACKGROUND: This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. PATIENTS AND METHODS: Patients (n = 76) receiving either taxanes (group A) or OV (group B) in combination with trastuzumab were identified from a breast cancer database. Progression-free survival (PFS) was defined as the primary study endpoint; secondary endpoints were overall survival (OS), response rate (RR), incidence of brain metastases, and brain metastases-free survival (BMFS). RESULTS: 36 patients received taxanes and 40 patients OV in combination with trastuzumab. At a median follow-up of 47.5 months, median PFS was 7 months (group A) and 9 months in group B (log-rank; non-significant), respective numbers for OS were 49 and 59 months (p = 0.033). The incidence of brain metastases did not differ significantly between the 2 treatment groups, whereas BMFS was significantly longer in patients receiving OV. CONCLUSIONS: OV plus trastuzumab yielded similar results in terms of PFS and RR and was superior in terms of OS and BMFS. These results add to the growing body of evidence that vinorelbine is a viable alternative to taxanes in HER2-positive metastatic breast cancer.
BACKGROUND: This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. PATIENTS AND METHODS: Patients (n = 76) receiving either taxanes (group A) or OV (group B) in combination with trastuzumab were identified from a breast cancer database. Progression-free survival (PFS) was defined as the primary study endpoint; secondary endpoints were overall survival (OS), response rate (RR), incidence of brain metastases, and brain metastases-free survival (BMFS). RESULTS: 36 patients received taxanes and 40 patientsOV in combination with trastuzumab. At a median follow-up of 47.5 months, median PFS was 7 months (group A) and 9 months in group B (log-rank; non-significant), respective numbers for OS were 49 and 59 months (p = 0.033). The incidence of brain metastases did not differ significantly between the 2 treatment groups, whereas BMFS was significantly longer in patients receiving OV. CONCLUSIONS:OV plus trastuzumab yielded similar results in terms of PFS and RR and was superior in terms of OS and BMFS. These results add to the growing body of evidence that vinorelbine is a viable alternative to taxanes in HER2-positive metastatic breast cancer.
Entities:
Keywords:
Brain metastases; HER2-positive breast cancer; Metastatic breast cancer; Oral vinorelbine; Taxanes; Trastuzumab
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: V Heinemann; D Di Gioia; U Vehling-Kaiser; H-D Harich; B Heinrich; A Welt; C Ziske; G Deutsch; R Pihusch; H Kölbl; S Hegewisch-Becker; M Michl; H J Stemmler Journal: Ann Oncol Date: 2010-08-19 Impact factor: 32.976
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Rupert Bartsch; Catharina Wenzel; Gabriela Altorjai; Ursula Pluschnig; Thomas Bachleitner-Hoffmann; Gottfried J Locker; Margaretha Rudas; Robert Mader; Christoph C Zielinski; Guenther G Steger Journal: Breast Cancer Res Treat Date: 2006-09-21 Impact factor: 4.872
Authors: Michael Andersson; Elisabeth Lidbrink; Karsten Bjerre; Erik Wist; Kristin Enevoldsen; Anders B Jensen; Per Karlsson; Ulla B Tange; Peter G Sørensen; Susanne Møller; Jonas Bergh; Sven T Langkjer Journal: J Clin Oncol Date: 2010-12-13 Impact factor: 44.544
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: C Catania; M Medici; E Magni; E Munzone; D Cardinale; L Adamoli; G Sanna; I Minchella; D Radice; A Goldhirsch; F Nolè Journal: Ann Oncol Date: 2007-09-09 Impact factor: 32.976
Authors: A Berghoff; Z Bago-Horvath; C De Vries; P Dubsky; U Pluschnig; M Rudas; A Rottenfusser; M Knauer; H Eiter; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger; M Preusser; R Bartsch Journal: Br J Cancer Date: 2012-01-10 Impact factor: 7.640
Authors: Markus Kuksis; Yizhuo Gao; William Tran; Christianne Hoey; Alex Kiss; Adam S Komorowski; Aman J Dhaliwal; Arjun Sahgal; Sunit Das; Kelvin K Chan; Katarzyna J Jerzak Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300